Evidence map›Paper›PMID 33554041›Full record

SynthesisJNCI cancer spectrum2021

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

Ana S Salazar, Malika Rakhmankulova, Laura E Simon, Adetunji T Toriola

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ana S SalazarDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-5617-5609
Malika RakhmankulovaDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.
Laura E SimonBernard Becker Medical Library, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-3760-6810
Adetunji T ToriolaDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-1079-2606
Washington University in St. Louis · US

Funding

Targeting RANK Pathway in Mammographic Density and Primary Breast Cancer PreventionR37CA235602 · NCI · WASHINGTON UNIVERSITY · PI TORIOLA, ADETUNJI T · 2019 to 2025
$4.2M
Metabolite Profiles and Mammographic Density in Premenopausal WomenR01CA246592 · NCI · WASHINGTON UNIVERSITY · PI TORIOLA, ADETUNJI T · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA246592NCI NIH HHS R37 CA235602
6 · The paper itself

Abstract

Background: Higher mammographic breast density (MBD) is associated with an increased risk of breast cancer when compared with lower MBD, especially in premenopausal women. However, little is known about the effectiveness of chemoprevention agents in reducing MBD in premenopausal women without a history of breast cancer. Findings from this review should provide insight on how to target MBD in breast cancer prevention in premenopausal women with dense breasts. Methods: We searched 9 electronic databases for clinical trials in English, Spanish, French, or German published until January 2020. Articles evaluating the association of pharmacological agents and MBD were included. Data were extracted on methods, type and dose of intervention, outcomes, side effects, and follow up. Quality of the studies was assessed using the US Preventive Services Task Force criteria. Results: We identified 7 clinical trials evaluating the associations of 6 chemoprevention agents with changes in MBD in premenopausal women without history of breast cancer. The studies evaluated selective estrogen-receptor modulators (n = 1); gonadotropin-releasing hormone agonists (n = 2); isoflavones (n = 1); vitamin D (n = 1); and Boswellia, betaine, and mayo-inositol compound (n = 1). Hormonal interventions were associated with net reductions in percent density (tamoxifen [13.4%], leuprolide acetate [8.9%], and goserelin [2.7%]), whereas nonhormonal (vitamin D and isoflavone) interventions were not. However, MBD returned to preintervention baseline levels after cessation of gonadotropin-releasing hormone agonists. Conclusions: A limited number of chemoprevention agents have been shown to reduce MBD in premenopausal women. Identification of new and well-tolerated chemoprevention agents targeting MBD and larger studies to confirm agents that have been studied in small trials are urgent priorities for primary breast cancer prevention in premenopausal women with dense breasts.

Indexed as

PremenopauseAnticarcinogenic AgentsBetaineBoswelliaBreast DensityDrug CombinationsFemaleGonadotropin-Releasing HormoneGoserelinHumansInositolIsoflavonesLeuprolideMammographyRandomized Controlled Trials as TopicSelective Estrogen Receptor ModulatorsAnticarcinogenic AgentsBetaineDrug CombinationsGonadotropin-Releasing HormoneGoserelinInositolIsoflavonesLeuprolideSelective Estrogen Receptor ModulatorsTamoxifenVitamin DVitamins

Identifiers

PMID33554041
PMCPMC7853173
OpenAlexW3124872373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.